Drug updated on 7/25/2024
Dosage Form | Injection (subcutaneous; 150 mg/mL) |
Drug Class | Interleukin-1β blockers |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of periodic fever syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: Familial Cold Auto-inflammatory Syndorme (FCAS) and Muckle-Wells Syndrome (MWS).
- Indicated for the treatment of periodic fever syndromes: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
- Indicated for the treatment of periodic fever syndromes: Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
- Indicated for the treatment of periodic fever syndromes: Familial Mediterranean Fever (FMF) in adult and pediatric patients.
- Indicated for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
- Indicated for the treatment of Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Canakinumab (Ilaris) is indicated for the treatment of periodic fever syndromes and gout flares in specific patient populations.
- The information was derived from 16 systematic reviews/meta-analyses studies.
- In treating gout flares, canakinumab showed superior effectiveness compared to standard treatments like NSAIDs and colchicine, with a favorable safety profile primarily in adult patients.
- For Familial Mediterranean Fever (FMF), canakinumab achieved up to 81% complete remission in pediatric patients, showing high effectiveness alongside Anakinra; adverse events were slightly higher in adults than children.
- Canakinumab demonstrated significant efficacy across various immune-mediated diseases such as CAPS, FMF, sJIA, and other IL-1 mediated conditions while being generally well-tolerated but associated with some respiratory infections and gastrointestinal issues.
- During pregnancy studies involving inflammatory disease treatments with canakinumab or anakinra, most babies were born healthy despite some preterm births; the focus was on safety rather than effectiveness.
- In Schnitzler syndrome cases reviewed across seven publications involving 34 patients, canakinumab provided a complete response rate of 58.6%, though infections were noted as frequent adverse events among this population group.
- For systemic juvenile idiopathic arthritis (sJIA), meta-analysis revealed that canakinumab had the highest probability of efficacy compared to other biologics like Anakinra or Tocilizumab without significant differences in serious adverse events between these treatments.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ilaris (canakinumab) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Adult-onset Still's disease: diagnosis and treatment according to the new S2e guidelines of the German Society of Rheumatology (DGRh). | 2023 | Die Dermatologie |